HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
03
11
2021
accepted:
05
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Antiviral NK cell activity is regulated through the interaction of activating and inhibitory NK cell receptors with their ligands on infected cells. HLA class I molecules serve as ligands for most killer cell immunoglobulin-like receptors (KIRs), but no HLA class I ligands for the inhibitory NK cell receptor KIR2DL5 have been identified to date. Using a NK cell receptor/ligand screening approach, we observed no strong binding of KIR2DL5 to HLA class I or class II molecules, but confirmed that KIR2DL5 binds to the poliovirus receptor (PVR, CD155). Functional studies using primary human NK cells revealed a significantly decreased degranulation of KIR2DL5+ NK cells in response to CD155-expressing target cells. We subsequently investigated the role of KIR2DL5/CD155 interactions in HIV-1 infection, and showed that multiple HIV-1 strains significantly decreased CD155 expression levels on HIV-1-infected primary human CD4+ T cells via a Nef-dependent mechanism. Co-culture of NK cells with HIV-1-infected CD4+ T cells revealed enhanced anti-viral activity of KIR2DL5+ NK cells against wild-type versus Nef-deficient viruses, indicating that HIV-1-mediated downregulation of CD155 renders infected cells more susceptible to recognition by KIR2DL5+ NK cells. These data show that CD155 suppresses the antiviral activity of KIR2DL5+ NK cells and is downmodulated by HIV-1 Nef protein as potential trade-off counteracting activating NK cell ligands, demonstrating the ability of NK cells to counteract immune escape mechanisms employed by HIV-1.
Identifiants
pubmed: 35749424
doi: 10.1371/journal.ppat.1010572
pii: PPATHOGENS-D-21-02208
pmc: PMC9231786
doi:
Substances chimiques
Antiviral Agents
0
Ligands
0
Receptors, Natural Killer Cell
0
Receptors, Virus
0
nef Gene Products, Human Immunodeficiency Virus
0
nef protein, Human immunodeficiency virus 1
0
nef protein, Human immunodeficiency virus 2
0
poliovirus receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010572Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sci Rep. 2017 May 25;7(1):2414
pubmed: 28546555
PLoS Med. 2015 Nov 17;12(11):e1001900; discussion e1001900
pubmed: 26575988
AIDS Res Hum Retroviruses. 2017 Feb;33(2):93-100
pubmed: 27296670
AIDS. 2017 Nov 13;31(17):2317-2330
pubmed: 28926399
J Acquir Immune Defic Syndr. 2016 May 1;72(1):1-10
pubmed: 26656785
J Virol. 2012 Mar;86(5):2715-28
pubmed: 22190722
J Immunol. 2000 Jun 1;164(11):5797-804
pubmed: 10820258
J Virol. 1994 May;68(5):2906-14
pubmed: 8151761
Retrovirology. 2013 Dec 03;10:146
pubmed: 24299076
J Exp Med. 2003 Aug 18;198(4):557-67
pubmed: 12913096
J Immunol. 2004 Apr 1;172(7):3994-8
pubmed: 15034010
Blood. 2003 Sep 15;102(6):2130-7
pubmed: 12775570
J Exp Med. 1994 Jan 1;179(1):115-23
pubmed: 7903679
J Gen Virol. 2013 Dec;94(Pt 12):2664-2669
pubmed: 24045107
J Immunol. 2004 Jun 15;172(12):7385-92
pubmed: 15187115
Hum Immunol. 2014 Aug;75(8):816-21
pubmed: 24929143
J Immunol. 1998 Jul 15;161(2):571-7
pubmed: 9670929
Med Microbiol Immunol. 2017 Dec;206(6):463-470
pubmed: 29032460
mBio. 2019 Jun 18;10(3):
pubmed: 31213558
Cell Host Microbe. 2016 May 11;19(5):686-95
pubmed: 27173934
Immunity. 1999 Jun;10(6):661-71
pubmed: 10403641
Nature. 1998 Jan 22;391(6665):397-401
pubmed: 9450757
Cell Host Microbe. 2016 May 11;19(5):570-1
pubmed: 27173922
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019260
Immunity. 1995 Dec;3(6):801-9
pubmed: 8777725
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Croat Med J. 2007 Dec;48(6):800-6
pubmed: 18074414
PLoS One. 2018 Jan 23;13(1):e0191733
pubmed: 29360870
PLoS Pathog. 2012;8(7):e1002805
pubmed: 22807681
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
pubmed: 23542380
Viruses. 2017 Oct 12;9(10):
pubmed: 29023371
Front Immunol. 2012 Sep 17;3:289
pubmed: 23060877
J Gen Virol. 2007 Jan;88(Pt 1):242-250
pubmed: 17170457
J Immunol. 1989 May 1;142(9):3320-8
pubmed: 2785140
Mol Cell Proteomics. 2019 Nov;18(11):2310-2323
pubmed: 31308249
J Immunol Res. 2021 Jan 13;2021:9053280
pubmed: 33521134
Nat Rev Immunol. 2015 Apr;15(4):243-54
pubmed: 25743219
Front Immunol. 2012 Aug 20;3:258
pubmed: 22934097
Nature. 2008 Jan 24;451(7177):425-30
pubmed: 18200009
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
J Virol. 2012 Apr;86(8):4496-504
pubmed: 22301152
AIDS. 2014 Jun 19;28(10):1399-408
pubmed: 24785948
Cell. 2020 Aug 20;182(4):1027-1043.e17
pubmed: 32822567
J Virol. 2019 Sep 30;93(20):
pubmed: 31375574
J Virol. 2001 Apr;75(8):3657-65
pubmed: 11264355
J Virol. 2002 May;76(9):4625-33
pubmed: 11932428
J Cell Biol. 2004 Dec 6;167(5):903-13
pubmed: 15569716
Annu Rev Immunol. 2013;31:163-94
pubmed: 23298212
J Immunol. 2007 Apr 1;178(7):4402-10
pubmed: 17371997
AIDS. 2020 May 1;34(6):801-813
pubmed: 32028328
Nat Immunol. 2019 Sep;20(9):1129-1137
pubmed: 31358998
Front Immunol. 2018 Oct 10;9:2341
pubmed: 30364127
Semin Immunol. 2006 Jun;18(3):145-50
pubmed: 16740393
J Virol. 2007 Dec;81(24):13852-64
pubmed: 17928336
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
Front Cell Infect Microbiol. 2020 May 05;10:175
pubmed: 32432050
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Virology. 2014 Sep;464-465:375-384
pubmed: 25113908
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982